Glycemic Control In Type 2 Diabetes Therapeutics
1. Avandia patent expiration
Treatment: Method of treatment of type ii diabetes; Use of avandia as monotherapy, in combination with metformin, and in combination with sulfonylureas to improve glycemic control in patients with type 2 diabete...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6288095 (Pediatric) | WOODWARD | Compounds |
Aug, 2017
(8 years ago) | |
|
US5741803 (Pediatric) | WOODWARD | Substituted thiazolidinedionle derivatives |
Oct, 2015
(10 years ago) | |
| US6288095 | WOODWARD | Compounds |
Feb, 2017
(8 years ago) | |
| US5741803 | WOODWARD | Substituted thiazolidinedionle derivatives |
Apr, 2015
(10 years ago) | |
| US7358366 | WOODWARD | Thiazolidinedione derivative and its use as antidiabetic |
Apr, 2020
(5 years ago) | |
|
US7358366 (Pediatric) | WOODWARD | Thiazolidinedione derivative and its use as antidiabetic |
Oct, 2020
(5 years ago) | |
Drugs and Companies using ROSIGLITAZONE MALEATE ingredient
Market Authorisation Date: 25 May, 1999
Dosage: TABLET
How can I launch a generic of AVANDIA before it's drug patent expiration?
More Information on Dosage
AVANDIA family patents
2. Invokana patent expiration
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascu...
INVOKANA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(1 year, 10 months from now) | |
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(3 years from now) | |
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(8 months ago) | |
| US10617668 | JANSSEN PHARMS | Pharmaceutical formulations |
May, 2031
(5 years from now) | |
|
US10617668 (Pediatric) | JANSSEN PHARMS | Pharmaceutical formulations |
Nov, 2031
(5 years from now) | |
|
US7943582 (Pediatric) | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Aug, 2029
(3 years from now) | |
|
US7943788 (Pediatric) | JANSSEN PHARMS | Glucopyranoside compound |
Jan, 2028
(2 years from now) | |
|
US8222219 (Pediatric) | JANSSEN PHARMS | Glucopyranoside compound |
Oct, 2025
(2 months ago) | |
|
US8513202 (Pediatric) | JANSSEN PHARMS | Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Jun, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-733) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Indication(I-809) | Sep 27, 2022 |
| New Patient Population(NPP) | Dec 18, 2027 |
| Pediatric Exclusivity(PED) | Jun 18, 2028 |
Drugs and Companies using CANAGLIFLOZIN ingredient
NCE-1 date: 19 June, 2027
Market Authorisation Date: 29 March, 2013
Dosage: TABLET
How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage
INVOKANA family patents
3. Nesina patent
expiration
Treatment: Methods of treating lipid metabolism and glycometabolism disorders comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer; Meth...
Can you believe NESINA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(2 years from now) | |
| US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6150383 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US6303661 | TAKEDA PHARMS USA | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(8 years ago) | |
| US6303640 | TAKEDA PHARMS USA | Pharmaceutical composition |
Aug, 2016
(9 years ago) | |
| US6211205 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US7078381 | TAKEDA PHARMS USA | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US7459428 | TAKEDA PHARMS USA | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US6329404 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(9 years ago) | |
| US6890898 | TAKEDA PHARMS USA | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(6 years ago) | |
| US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Dec, 2025
(a month ago) | |
| US8697125 | TAKEDA PHARMS USA | Tablet preparation without causing a tableting trouble |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
| M(M-177) | Apr 05, 2019 |
| M(M-300) | Jul 27, 2026 |
Drugs and Companies using ALOGLIPTIN BENZOATE ingredient
NCE-1 date: 25 January, 2017
Market Authorisation Date: 25 January, 2013
Dosage: TABLET
How can I launch a generic of NESINA before it's drug patent expiration?
More Information on Dosage
NESINA family patents
4. Onglyza patent expiration
Treatment: Method for treating type ii diabetes by administering saxagliptin
ONGLYZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395767 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Feb, 2021
(4 years ago) | |
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(2 years ago) | |
| US7951400 | ASTRAZENECA AB | Coated tablet formulation and method |
Nov, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2014 |
| M(M-108) | Dec 16, 2014 |
| M(M-134) | May 24, 2016 |
| M(M-175) | Apr 05, 2019 |
| M(M-198) | Feb 27, 2020 |
Drugs and Companies using SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2013
Market Authorisation Date: 31 July, 2009
Dosage: TABLET
How can I launch a generic of ONGLYZA before it's drug patent expiration?
More Information on Dosage
ONGLYZA family patents
5. Welchol patent expiration
Treatment: Use as a bile acid sequestrant for lowering cholesterol; A method for reducing serum glucose levels in adults with type 2 diabetes mellitus; Use as a bile acid sequestrant
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5693675 | COSETTE | Alkylated amine polymers |
Dec, 2014
(11 years ago) | |
| US6784254 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US6433026 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US5607669 | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Jun, 2014
(11 years ago) | |
| US5679717 | COSETTE | Method for removing bile salts from a patient with alkylated amine polymers |
Apr, 2014
(11 years ago) | |
| US7229613 | COSETTE | Method for lowering serum glucose |
Apr, 2022
(3 years ago) | |
| US6066678 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US5919832 | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Apr, 2014
(11 years ago) | |
| US5917007 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US7101960 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
|
US5917007 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US5693675 (Pediatric) | COSETTE | Alkylated amine polymers |
Jun, 2015
(10 years ago) | |
|
US5679717 (Pediatric) | COSETTE | Method for removing bile salts from a patient with alkylated amine polymers |
Oct, 2014
(11 years ago) | |
|
US6066678 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US5607669 (Pediatric) | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Dec, 2014
(11 years ago) | |
|
US5919832 (Pediatric) | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Oct, 2014
(11 years ago) | |
|
US6433026 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US6784254 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US7101960 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US7229613 (Pediatric) | COSETTE | Method for lowering serum glucose |
Oct, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-608) | Oct 02, 2012 |
| Pediatric Exclusivity(PED) | Apr 02, 2013 |
| M(M-232) | Oct 20, 2024 |
Drugs and Companies using COLESEVELAM HYDROCHLORIDE ingredient
Market Authorisation Date: 26 May, 2000
Dosage: CAPSULE; FOR SUSPENSION; TABLET; BAR, CHEWABLE
How can I launch a generic of WELCHOL before it's drug patent expiration?
More Information on Dosage
WELCHOL family patents